Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
PARIS, Jan. 29, 2016 -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2016.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
| -- 2015 Full-Year Results | March 7, 2016 | |||
| -- Shareholders’ AGM | April 12, 2016 | |||
| -- 2016 Half-Year results | October 14, 2016 |
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
